EA201490254A1 - Комбинированное лечение гепатита с - Google Patents

Комбинированное лечение гепатита с

Info

Publication number
EA201490254A1
EA201490254A1 EA201490254A EA201490254A EA201490254A1 EA 201490254 A1 EA201490254 A1 EA 201490254A1 EA 201490254 A EA201490254 A EA 201490254A EA 201490254 A EA201490254 A EA 201490254A EA 201490254 A1 EA201490254 A1 EA 201490254A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hepatitis
combined treatment
treatment
formulas
administering
Prior art date
Application number
EA201490254A
Other languages
English (en)
Russian (ru)
Inventor
Джил Уокер
Кристиан Фойтенлейтнер
Original Assignee
ГЛАКСОСМИТКЛАЙН ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ГЛАКСОСМИТКЛАЙН ЭлЭлСи filed Critical ГЛАКСОСМИТКЛАЙН ЭлЭлСи
Publication of EA201490254A1 publication Critical patent/EA201490254A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EA201490254A 2011-08-24 2012-08-24 Комбинированное лечение гепатита с EA201490254A1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161526798P 2011-08-24 2011-08-24
US201161529358P 2011-08-31 2011-08-31
US201261617813P 2012-03-30 2012-03-30
PCT/US2012/052216 WO2013028953A1 (en) 2011-08-24 2012-08-24 Combination treatments for hepatitis c

Publications (1)

Publication Number Publication Date
EA201490254A1 true EA201490254A1 (ru) 2014-07-30

Family

ID=47746891

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201490254A EA201490254A1 (ru) 2011-08-24 2012-08-24 Комбинированное лечение гепатита с

Country Status (18)

Country Link
US (1) US20140234253A1 (enExample)
EP (1) EP2747569A4 (enExample)
JP (2) JP2014527061A (enExample)
KR (1) KR20140065427A (enExample)
CN (1) CN103917095A (enExample)
AU (1) AU2012298750A1 (enExample)
BR (1) BR112014004182A2 (enExample)
CA (1) CA2845321A1 (enExample)
CL (1) CL2014000428A1 (enExample)
CO (1) CO6890100A2 (enExample)
CR (1) CR20140086A (enExample)
EA (1) EA201490254A1 (enExample)
HK (1) HK1198869A1 (enExample)
IL (1) IL230844A0 (enExample)
MX (1) MX2014002171A (enExample)
PH (1) PH12014500386A1 (enExample)
SG (1) SG2014010490A (enExample)
WO (1) WO2013028953A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120993A1 (es) * 2009-09-04 2012-08-22 Janssen Pharmaceuticals Inc Derivados bifenilicos como antivirales
KR101975233B1 (ko) 2011-08-17 2019-05-07 글락소스미스클라인 엘엘씨 치료 방법
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
PT107894A (pt) 2011-10-21 2014-10-31 Abbvie Inc Métodos para o tratamento de hcv compreendendo pelo menos dois agentes antivirais de actuação directa, ribavirina, mas não interferão.
GB2515942A (en) 2011-10-21 2015-01-07 Abbvie Inc Combination treatment (e.g. with ABT-072 or ABT-333) of DAAs for use in treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN105705511A (zh) 2013-04-12 2016-06-22 艾其林医药公司 用于治疗hcv的氘化核苷前药
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
EP3019196B1 (en) * 2013-07-09 2018-06-06 Bristol-Myers Squibb Company Combinations of hepatitis c virus inhibitors
WO2015009744A1 (en) 2013-07-17 2015-01-22 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of hcv
CN104725365B (zh) * 2013-12-23 2019-02-26 南京圣和药业股份有限公司 丙型肝炎病毒抑制剂及其应用
CA2935089C (en) * 2013-12-31 2018-11-27 Nanjing Sanhome Pharmaceutical Co., Ltd. 9,9,10,10-tetrafluoro-9,10-dihydrophenanthrene hepatitis c virus inhibitor and application thereof
CN106279121B (zh) * 2014-01-21 2019-05-24 杭州普晒医药科技有限公司 一种化合物的盐及晶型或无定型物、其制备方法、含有它们的药物组合物和用途
SG11201703645XA (en) * 2014-11-10 2017-06-29 Glaxosmithkline Intellectual Property (No 2) Ltd Long acting pharmaceutical compositions for hepatitis c
MA41812A (fr) * 2015-03-27 2018-01-30 Janssen Pharmaceuticals Inc Procédés et intermédiaires pour la préparation d'un inhibiteur de protéase macrocyclique du vhc
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
CN110693887B (zh) * 2019-05-17 2022-06-17 歌礼药业（浙江）有限公司 包含索磷布韦和拉维达韦的片剂及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100158862A1 (en) * 2006-08-11 2010-06-24 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8329159B2 (en) * 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8303944B2 (en) * 2006-08-11 2012-11-06 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7704992B2 (en) * 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
ES2435799T3 (es) * 2008-10-09 2013-12-23 Anadys Pharmaceuticals, Inc. Un método de inhibición del virus de la hepatitis C mediante combinación de una 5,6-dihidro-1H-piridin-2-ona y de uno o más compuestos antivirales adicionales
WO2010062821A1 (en) * 2008-11-28 2010-06-03 Glaxosmithkline Llc Anti-viral compounds, compositions, and methods of use
MX2011007195A (es) * 2009-01-07 2013-07-12 Scynexis Inc Derivado de ciclosporina para el uso en el tratamiento de infección de virus de hepatitis c (vhc) y virus de inmunodeficiencia humana (vih).
MX363732B (es) * 2009-05-13 2019-04-01 Gilead Pharmasset Llc Star Compuestos antivirales.
PE20120993A1 (es) * 2009-09-04 2012-08-22 Janssen Pharmaceuticals Inc Derivados bifenilicos como antivirales
US8415374B2 (en) * 2009-10-12 2013-04-09 Bristol-Myers Squibb Company Combinations of hepatitis C virus inhibitors
US8377980B2 (en) * 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2784748A1 (en) * 2009-12-18 2011-06-23 Idenix Pharmaceuticals, Inc. 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
WO2012040126A1 (en) * 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs

Also Published As

Publication number Publication date
BR112014004182A2 (pt) 2017-03-14
IL230844A0 (en) 2014-03-31
HK1198869A1 (en) 2015-06-19
KR20140065427A (ko) 2014-05-29
EP2747569A1 (en) 2014-07-02
CN103917095A (zh) 2014-07-09
AU2012298750A1 (en) 2014-03-13
CR20140086A (es) 2014-05-02
JP2014527061A (ja) 2014-10-09
CO6890100A2 (es) 2014-03-10
WO2013028953A1 (en) 2013-02-28
SG2014010490A (en) 2014-04-28
MX2014002171A (es) 2014-04-25
JP2017165746A (ja) 2017-09-21
CL2014000428A1 (es) 2014-08-01
US20140234253A1 (en) 2014-08-21
PH12014500386A1 (en) 2019-10-07
CA2845321A1 (en) 2013-02-28
EP2747569A4 (en) 2015-07-08

Similar Documents

Publication Publication Date Title
EA201490254A1 (ru) Комбинированное лечение гепатита с
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
EA201890146A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
EA201290919A1 (ru) Индазольные соединения и их применение
EA201101507A1 (ru) Способы лечения солидных опухолей
EA201692506A2 (ru) Ингибиторы репликации вирусов гриппа
EA201591363A1 (ru) Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn
UA117451C2 (uk) Терапевтично активні сполуки і способи їх застосування
EA201391108A1 (ru) Лечение липодистрофии
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
EA201391485A1 (ru) Способы и композиции для лечения нейродегенеративных заболеваний
EA201490377A1 (ru) Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата
EA201390428A1 (ru) Композиции и способы лечения легочной гипертензии
EA201490516A1 (ru) Бифенилкарбоксиамиды в качестве ингибиторов rock-киназ
EA201490378A1 (ru) ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β
MX382162B (es) Combinaciones farmacéuticas de un inhibidor de enzima hdac con un inhibidor de proteasoma, y su uso en el tratamiento de cáncer.
MX2014003180A (es) Metodos para tratar vhc.
EA201370230A1 (ru) Новые ингибиторы rock
EA201491500A1 (ru) Способы лечения фиброза
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
EA201300421A1 (ru) Комбинированная терапия для лечения инфекции hcv
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний